Dynavax Technologies Corporation (DVAX)
USD 10.39
(-2.44%)
USD 10.39
(-2.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -37.02 Million USD | -113.06% |
| 2022 | 283.52 Million USD | 110.82% |
| 2021 | 134.48 Million USD | 278.79% |
| 2020 | -75.22 Million USD | 38.08% |
| 2019 | -121.48 Million USD | 20.76% |
| 2018 | -153.31 Million USD | -59.7% |
| 2017 | -96 Million USD | 13.28% |
| 2016 | -110.7 Million USD | -5.36% |
| 2015 | -105.07 Million USD | -15.07% |
| 2014 | -91.31 Million USD | -37.33% |
| 2013 | -66.48 Million USD | 1.64% |
| 2012 | -67.59 Million USD | -42.08% |
| 2011 | -47.57 Million USD | 0.03% |
| 2010 | -47.58 Million USD | -214.85% |
| 2009 | -15.11 Million USD | 37.33% |
| 2008 | -24.12 Million USD | 66.07% |
| 2007 | -71.09 Million USD | -9.4% |
| 2006 | -64.98 Million USD | -188.94% |
| 2005 | -22.49 Million USD | -33.39% |
| 2004 | -16.86 Million USD | 5.09% |
| 2003 | -17.76 Million USD | 4.8% |
| 2002 | -18.65 Million USD | 4.46% |
| 2001 | -19.53 Million USD | -102.1% |
| 2000 | -9.66 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 6.06 Million USD | 136.55% |
| 2024 Q1 | -16.57 Million USD | -95.27% |
| 2023 Q2 | -3.4 Million USD | 81.01% |
| 2023 Q1 | -17.93 Million USD | -128.41% |
| 2023 Q4 | -8.49 Million USD | -265.97% |
| 2023 Q3 | 5.11 Million USD | 250.25% |
| 2023 FY | -37.02 Million USD | -113.06% |
| 2022 Q2 | 128.22 Million USD | 316.82% |
| 2022 FY | 283.52 Million USD | 110.82% |
| 2022 Q4 | 63.13 Million USD | 2.83% |
| 2022 Q3 | 61.39 Million USD | -52.12% |
| 2022 Q1 | 30.76 Million USD | -61.89% |
| 2021 Q3 | 16.06 Million USD | 75.19% |
| 2021 Q2 | 9.17 Million USD | -67.85% |
| 2021 Q4 | 80.71 Million USD | 402.35% |
| 2021 Q1 | 28.52 Million USD | 339.84% |
| 2021 FY | 134.48 Million USD | 278.79% |
| 2020 Q3 | -13.82 Million USD | 40.76% |
| 2020 Q2 | -23.33 Million USD | -20.85% |
| 2020 FY | -75.22 Million USD | 38.08% |
| 2020 Q4 | -11.89 Million USD | 13.96% |
| 2020 Q1 | -19.31 Million USD | 29.49% |
| 2019 FY | -121.48 Million USD | 20.76% |
| 2019 Q1 | -37.85 Million USD | 0.28% |
| 2019 Q2 | -38.97 Million USD | -2.95% |
| 2019 Q3 | -30.62 Million USD | 21.41% |
| 2019 Q4 | -27.38 Million USD | 10.58% |
| 2018 Q3 | -38.89 Million USD | -1.97% |
| 2018 FY | -153.31 Million USD | -59.7% |
| 2018 Q1 | -38.31 Million USD | -37.62% |
| 2018 Q2 | -38.14 Million USD | 0.44% |
| 2018 Q4 | -37.96 Million USD | 2.41% |
| 2017 Q2 | -20.32 Million USD | 20.16% |
| 2017 FY | -96 Million USD | 13.28% |
| 2017 Q4 | -27.84 Million USD | -24.34% |
| 2017 Q3 | -22.39 Million USD | -10.19% |
| 2017 Q1 | -25.45 Million USD | -31.73% |
| 2016 Q1 | -27.29 Million USD | -1.29% |
| 2016 Q2 | -29.25 Million USD | -7.18% |
| 2016 Q4 | -19.32 Million USD | 44.54% |
| 2016 Q3 | -34.83 Million USD | -19.09% |
| 2016 FY | -110.7 Million USD | -5.36% |
| 2015 Q1 | -26.45 Million USD | -18.02% |
| 2015 Q2 | -23.23 Million USD | 12.17% |
| 2015 Q4 | -26.94 Million USD | 5.26% |
| 2015 Q3 | -28.44 Million USD | -22.41% |
| 2015 FY | -105.07 Million USD | -15.07% |
| 2014 FY | -91.31 Million USD | -37.33% |
| 2014 Q4 | -22.41 Million USD | 25.48% |
| 2014 Q1 | -13.96 Million USD | -7.5% |
| 2014 Q2 | -24.85 Million USD | -77.95% |
| 2014 Q3 | -30.07 Million USD | -21.01% |
| 2013 Q3 | -15.56 Million USD | 8.69% |
| 2013 Q4 | -12.99 Million USD | 16.55% |
| 2013 Q1 | -20.87 Million USD | -4.38% |
| 2013 FY | -66.48 Million USD | 1.64% |
| 2013 Q2 | -17.04 Million USD | 18.34% |
| 2012 Q3 | -17.09 Million USD | -16.71% |
| 2012 Q2 | -14.64 Million USD | 7.57% |
| 2012 Q1 | -15.84 Million USD | -234.77% |
| 2012 FY | -67.59 Million USD | -42.08% |
| 2012 Q4 | -20 Million USD | -16.99% |
| 2011 FY | -47.57 Million USD | 0.03% |
| 2011 Q4 | -4.73 Million USD | 68.06% |
| 2011 Q1 | -17.92 Million USD | -14.81% |
| 2011 Q2 | -10.09 Million USD | 43.68% |
| 2011 Q3 | -14.82 Million USD | -46.79% |
| 2010 Q3 | -6.75 Million USD | 58.51% |
| 2010 Q1 | -8.95 Million USD | 22.93% |
| 2010 Q2 | -16.27 Million USD | -81.79% |
| 2010 FY | -47.58 Million USD | -214.85% |
| 2010 Q4 | -15.61 Million USD | -131.3% |
| 2009 Q4 | -11.61 Million USD | -8.43% |
| 2009 FY | -15.11 Million USD | 37.33% |
| 2009 Q3 | -10.71 Million USD | -473.6% |
| 2009 Q2 | 2.86 Million USD | -33.99% |
| 2009 Q1 | 4.34 Million USD | 129.55% |
| 2008 Q2 | -6.63 Million USD | 51.31% |
| 2008 Q1 | -13.62 Million USD | 2.82% |
| 2008 FY | -24.12 Million USD | 66.07% |
| 2008 Q4 | 1.89 Million USD | 132.86% |
| 2008 Q3 | -5.75 Million USD | 13.21% |
| 2007 Q4 | -14.01 Million USD | 26.9% |
| 2007 Q3 | -19.17 Million USD | 12.13% |
| 2007 Q2 | -21.82 Million USD | -35.72% |
| 2007 Q1 | -16.07 Million USD | 26.88% |
| 2007 FY | -71.09 Million USD | -9.4% |
| 2006 Q1 | -8.9 Million USD | 5.93% |
| 2006 Q2 | -17.98 Million USD | -101.96% |
| 2006 FY | -64.98 Million USD | -188.94% |
| 2006 Q3 | -16.09 Million USD | 10.52% |
| 2006 Q4 | -21.99 Million USD | -36.62% |
| 2005 Q3 | -8.71 Million USD | 3.34% |
| 2005 Q4 | -9.46 Million USD | -8.68% |
| 2005 FY | -22.49 Million USD | -33.39% |
| 2005 Q1 | 4.7 Million USD | 185.59% |
| 2005 Q2 | -9.01 Million USD | -291.64% |
| 2004 Q3 | -4.28 Million USD | -38.45% |
| 2004 Q4 | -5.49 Million USD | -28.24% |
| 2004 Q1 | -3.98 Million USD | 77.72% |
| 2004 FY | -16.86 Million USD | 5.09% |
| 2004 Q2 | -3.09 Million USD | 22.33% |
| 2003 FY | -17.76 Million USD | 4.8% |
| 2003 Q2 | 96 Thousand USD | 102.03% |
| 2003 Q3 | 23 Thousand USD | -76.04% |
| 2003 Q1 | -4.71 Million USD | 0.0% |
| 2003 Q4 | -17.88 Million USD | -77852.17% |
| 2002 FY | -18.65 Million USD | 4.46% |
| 2001 FY | -19.53 Million USD | -102.1% |
| 2000 FY | -9.66 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 122.178% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -1372.159% |
| Embecta Corp. | 221.5 Million USD | 116.717% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 142.233% |
| PainReform Ltd. | -9.58 Million USD | -286.352% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -673.787% |
| SCYNEXIS, Inc. | 72.66 Million USD | 150.954% |
| Journey Medical Corporation | -2.07 Million USD | -1686.204% |
| Safety Shot Inc | -12.18 Million USD | -203.903% |
| Alpha Teknova, Inc. | -35.56 Million USD | -4.119% |
| Bright Green Corporation | -8.89 Million USD | -316.448% |
| Procaps Group, S.A. | 38.97 Million USD | 195.009% |
| Alvotech | -354.86 Million USD | 89.565% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 178.832% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -145.186% |
| Cosmos Health Inc. | -21.83 Million USD | -69.61% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 76.197% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 76.768% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -673.787% |
| Theratechnologies Inc. | -10.62 Million USD | -248.433% |
| Harrow Health, Inc. | 580 Thousand USD | 6484.138% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -687.662% |
| Biofrontera Inc. | -22.67 Million USD | -63.284% |
| DURECT Corporation | -36.88 Million USD | -0.39% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -602.752% |
| Cronos Group Inc. | -81.37 Million USD | 54.497% |
| OptiNose, Inc. | -22.74 Million USD | -62.775% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 117.714% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 5.427% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 393.129% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 395.633% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -753.904% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -496.185% |
| Radius Health, Inc. | -3.92 Million USD | -843.389% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -949.911% |
| ProPhase Labs, Inc. | -21.61 Million USD | -71.323% |
| Phibro Animal Health Corporation | 53.31 Million USD | 169.451% |
| Procaps Group S.A. | 52.32 Million USD | 170.767% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -334.448% |
| Viatris Inc. | 766.2 Million USD | 104.833% |
| Rockwell Medical, Inc. | -6.67 Million USD | -455.142% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -604.758% |
| SIGA Technologies, Inc. | 83.62 Million USD | 144.281% |
| Tilray Brands, Inc. | -174.74 Million USD | 78.81% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 496.828% |
| Shineco, Inc. | -17.06 Million USD | -116.971% |
| PetIQ, Inc. | 60.01 Million USD | 161.698% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -681.721% |
| Incannex Healthcare Limited | -30.04 Million USD | -23.258% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 114.758% |
| Alimera Sciences, Inc. | -1.47 Million USD | -2417.199% |
| Silver Spike Investment Corp. | 7.34 Million USD | 604.461% |
| Assertio Holdings, Inc. | -243.53 Million USD | 84.796% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -528.405% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -171.918% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | -137.45% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -84.678% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 73.139% |
| Hempacco Co., Inc. | -8.81 Million USD | -320.186% |
| Talphera, Inc. | -16.88 Million USD | -119.243% |
| Alvotech | -354.86 Million USD | 89.565% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 169.271% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 110.155% |
| Currenc Group, Inc. | -6.64 Million USD | -457.165% |
| Kamada Ltd. | 10.06 Million USD | 467.925% |
| Indivior PLC | -4 Million USD | -825.7% |
| Evoke Pharma, Inc. | -7.43 Million USD | -398.298% |
| Flora Growth Corp. | -50.35 Million USD | 26.465% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -84.678% |
| Evolus, Inc. | -49.23 Million USD | 24.79% |
| HUTCHMED (China) Limited | 18.37 Million USD | 301.513% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 118.797% |
| Akanda Corp. | -10.05 Million USD | -268.387% |